Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The objective of the trial is to compare Progression free survival between GEMOX
(gemcitabine/oxaliplatin)vs XELOX(capecitabine/oxaliplatin)in metastatic or unresectable
Biliary tract carcinoma patients.